By Topic
Can Aristocrat Leisure (ASX: ALL) Extend Its Margin Expansion as Gaming Strength and Interactive Momentum Converge?
Aristocrat Leisure (ASX: ALL) delivers strong HY26 growth, expanding margins and cash generation across Gaming, Social Casino and iLottery, positioning the company for sustained earnings momentum and a multi year re rating. With NPATA up 8% (16% in constant currency), EBITDA up 6%, and segment profit expanding in constant currency, ALL has shown an expanding competitive advantage, strong cash generation, and a clear path to sustained NPATA growth.
BlueScope Steel (ASX: BSL) Breaks Higher as Investors Bet on Further Upside
BlueScope Steel shares have strengthened on improving earnings and investor confidence. The company is expanding production, upgrading facilities, and investing in low-emission steelmaking projects, positioning itself for long-term growth while maintaining exposure to global construction and infrastructure markets.
What is the reason behind the last 12-month rally in zinc prices, and how to get exposure on the ASX?
Zinc prices have surged over the past year due to supply shortages, mine disruptions, and strong demand from infrastructure and renewable energy projects. ASX investors can gain exposure through South32, Develop Global, and Sandfire Resources, each offering different risk and growth profiles.
NEXTDC (ASX: NXT): AI Demand Is Surging, but Earnings Must Catch Up Before the Next Leg Higher
NEXTDC (ASX: NXT) delivers strong revenue growth and record contracted utilisation, but heavy capex and negative statutory earnings cap near-term upside. AI-driven demand supports a justified premium, yet a sustained re-rating requires profitability acceleration and clearer cash-flow visibility.
Is Breakout in Clinuvel Pharmaceuticals (ASX: CUV) Signalling a Sustainable Bullish Reversal?
CLINUVEL is a global photomedicine group commercialising SCENESSE for rare disorders while advancing vitiligo, ACTH and porphyria programs. Recent share strength reflects EMA vitiligo progress, stronger pipeline visibility and Nasdaq listing plans, though Phase III, regulatory and competition risks remain.
Avecho Biotechnology (ASX: AVE): Breakout Above Long-Term Resistance Puts Trend Sustainability in Focus
Avecho’s rally reflects Phase III CBD-insomnia progress, patent wins, and improving investor confidence. The biotech commercialises its TPM delivery platform across pharma, skincare, and animal health, while its production business supports higher-risk human health programs.
...